Lipid Metabolism & Dietary Fats

Citation model. Claims grounded in AllNutrition's trust-scored library carry an inline bracketed reference [n] linking to the References section, which lists each source's evidence level and AllNutrition trust score (0–1). Where an AllNutrition query returned an overall evidence_strength and consensus_level, those labels are surfaced in the Evidence Review so readers can calibrate confidence. Only sources actually returned by the tool are cited; no trust scores are invented.

---

1. Introduction

Few topics in clinical nutrition generate as much public confusion — and as much genuine scientific nuance — as dietary fat. The "diet-heart hypothesis" that dominated the twentieth century collapsed saturated fat, cholesterol, and cardiovascular disease into a single simple story: eat less fat, especially saturated fat, and you will have less heart disease. That story is neither entirely wrong nor entirely right. Modern lipidology has replaced it with something more precise but also more demanding of the clinician: cardiovascular risk is driven by the number and behavior of atherogenic lipoprotein particles, and dietary fat quality — not fat quantity alone — shapes that particle burden [2][4]. Saturated fat, trans fat, monounsaturated fat, and the two families of polyunsaturated fat (omega-6 and omega-3) each have distinct, mechanistically grounded, and differently-evidenced relationships with lipoproteins and hard cardiovascular outcomes.

This module builds the biochemical scaffold — chylomicrons, VLDL, LDL, HDL, apoB, Lp(a), de novo lipogenesis, and fatty-acid oxidation — and then applies the appraisal discipline from Module 01 to the field's most contested questions: does replacing saturated fat with polyunsaturated fat or refined carbohydrate actually change cardiovascular outcomes, and by how much [7][8]? What does the divergence between REDUCE-IT, VITAL, ASCEND, and STRENGTH tell us about omega-3 supplementation [24][25]? Is dietary cholesterol from eggs still a legitimate concern [34][36]? Precision matters clinically, because patients arrive having heard every version of these claims from media and marketing, and the physician who can distinguish established mechanism from contested magnitude of effect earns durable trust.

2. Learning Objectives

By the end of this module, the learner will be able to:

1. Describe the exogenous and endogenous lipoprotein pathways — chylomicrons, VLDL, IDL, LDL, HDL — and explain why apoB particle count and Lp(a) are mechanistically superior atherogenic risk markers to LDL-C alone [1][2][4].
2. Classify dietary fatty acids by structure (saturated chain length, monounsaturated, omega-6 and omega-3 polyunsaturated, industrial trans) and describe their differential effects on lipoprotein metabolism [7][10][14].
3. Critically appraise the "substitution question" for saturated fat — replacement with PUFA, MUFA, whole-grain carbohydrate, or refined carbohydrate — including the strengths and limits of the major meta-analyses [7][8][9].
4. Summarize the trans-fat evidence base and the public-health response to it, and explain why it is among the least controversial claims in nutrition [7][13][51].
5. Evaluate the omega-3 EPA/DHA cardiovascular evidence, including the divergent results of REDUCE-IT, VITAL, ASCEND, STRENGTH, and OMEMI, the EPA-versus-DHA question, the fish-versus-supplement question, dose-response for triglycerides, and the atrial fibrillation signal [24][25][26][27][30].
6. Explain de novo lipogenesis and mitochondrial fatty-acid β-oxidation at the enzyme level, including the role of SREBP1c/ChREBP and the carnitine shuttle (CPT1/CACT/CPT2) [39][40].
7. Apply current guideline targets for total fat, saturated fat, and omega-3 intake to clinical counseling, including relevant drug interactions [43][44][45].

3. Scientific Foundations

3.1 Lipoprotein metabolism: the transport system for a compositional exposure

Dietary and endogenous lipids are insoluble in plasma and must be packaged into lipoproteins — spherical particles with a triglyceride/cholesteryl-ester core, a phospholipid monolayer, and surface apolipoproteins that determine each particle's metabolic fate [2]. Two parallel pathways move lipid through the body [2]. The exogenous pathway begins in the intestinal enterocyte, which packages absorbed dietary triglyceride and cholesterol into chylomicrons; peripheral lipoprotein lipase (LPL) hydrolyzes chylomicron triglyceride to free fatty acids for muscle/adipose uptake, and the depleted chylomicron remnant is cleared hepatically [2][6]. Loss-of-function mutations in the LPL-anchoring protein GPIHBP1 cause severe chylomicronemia, underscoring the pathway's dependence on functional LPL [6]. The endogenous pathway begins with hepatic VLDL assembly; like chylomicrons, VLDL is progressively delipidated by LPL through an IDL intermediate to LDL [2]. LDL is cleared chiefly via hepatic LDL-receptor-mediated endocytosis; particles escaping clearance can enter the arterial intima, where oxidative modification drives macrophage uptake and foam cell formation — the initiating atherosclerotic lesion [2]. HDL, assembled around apoA-I, performs reverse cholesterol transport; its cardioprotective value depends on particle function, not HDL-C concentration alone — high CETP activity can predict coronary disease even with elevated HDL-C, indicating dysfunctional particle remodeling [5].

ApoB, present once per particle across the VLDL→IDL→LDL lineage, directly counts circulating atherogenic particles and is a more accurate discordance-resolving risk marker than LDL-C [4]. Lp(a) is an LDL-like particle with apolipoprotein(a) covalently linked to apoB-100; it is 70–90% genetically determined, essentially diet-independent, and an independent, likely causal risk factor for atherosclerotic disease and aortic stenosis via endothelial dysfunction and pro-thrombotic (plasminogen-mimicking) mechanisms [4]. Metabolic-syndrome states can generate pathogenic subspecies such as electronegative LDL, via a hepatic lysophosphatidylcholine–HIF-1α–apoE pathway that redirects uptake to the scavenger receptor LOX-1 [3]. GLP-1 receptor agonism reduces hepatic VLDL production and apoC-III, accelerating triglyceride-rich lipoprotein clearance independent of weight loss — a mechanistic bridge to incretin therapy in dyslipidemia [1].

3.2 Dietary fatty acid classes and their metabolic signatures

Saturated fatty acids (SFA) are not metabolically uniform. Effects vary by chain length: longer-chain SFAs (C12–C18, dominant in red meat and butter) are most consistently linked to higher LDL-C and coronary risk, while very-long-chain (>C24) and short/medium-chain SFAs appear neutral or cardioprotective in some analyses [10][14]. Source matters as much as chemistry — SFA embedded in a fermented-dairy matrix behaves differently from SFA in processed meat (§3.4) [48].

Trans-fatty acids, chiefly industrial products of partial hydrogenation, uniquely raise LDL-C while lowering HDL-C, stimulate hepatic lipogenic transcription factors (PGC-1β, SREBP1c/1a) that elevate VLDL-triglyceride, and raise CRP [13][7] — a combination of adverse mechanisms across every major pathway, which is why trans fat is treated as categorically harmful rather than merely "worse than the alternative."

Monounsaturated fatty acids (MUFA), chiefly oleic acid from olive oil, nuts, and avocado, produce modest but consistent reductions in LDL-C and total cholesterol (pooled ≈−0.11 and −0.13 mmol/L respectively) when displacing saturated fat, alongside small apoA-I increases, reduced LDL oxidation via olive-oil phenolics (hydroxytyrosol, oleuropein), improved endothelial function, and reduced NF-κB–driven inflammatory gene expression [16][17][18][19].

Polyunsaturated fatty acids (PUFA) split into two families with different, sometimes competing, biology. Omega-6 linoleic acid (LA), the dominant PUFA in vegetable/seed oils, lowers LDL-C and total cholesterol dose-dependently and associates with lower stroke risk and all-cause mortality in large observational/RCT data [21][22][23]. LA converts inefficiently to arachidonic acid in humans and generates anti-inflammatory lipoxins alongside eicosanoid precursors, which is why RCTs generally show reduced, not increased, CRP when LA-rich oils replace saturated fat [12][21]. The competing hypothesis — that high LA intake displaces omega-3 status and shifts lipid-mediator balance pro-inflammatory — has direct RCT support: raising LA from 2.5% to 10% of energy significantly lowered plasma EPA without changing arachidonic acid [22]. This is a genuine, unresolved mechanistic tension (see §5).

Omega-3 PUFA — ALA (plant-derived) and the marine long-chain fatty acids EPA and DHA — are discussed in depth in §3.3 given their outsized role in the current controversy landscape.

3.3 The saturated-fat substitution question and the omega-3 cardiovascular trial landscape

The central methodological lesson of this module (echoing Module 01) is that saturated fat has no intrinsic effect — only an effect relative to what it is compared against [7][9]. A recent RCT meta-analysis of SFA modification (17 trials, 66,337 participants) found that replacing SFA primarily with PUFA reduced non-fatal myocardial infarction by roughly 25%, with no significant reduction in CVD or all-cause mortality; benefit concentrated in high-baseline-risk individuals (≈21 fewer non-fatal MIs/1,000 treated) versus a negligible effect at low risk [7]. An earlier, narrower secondary-prevention meta-regression found no significant benefit or harm from SFA-to-PUFA substitution but did find benefit from SFA-to-MUFA substitution — comparator choice, population risk, and trial selection materially change the conclusion [8]. Replacing SFA with refined carbohydrate is consistently classified as harmful (raises triglycerides via hepatic lipogenesis, worsens insulin signaling, raises CRP), whereas replacing SFA with whole grains or MUFA is protective — "low saturated fat" is an incomplete instruction without a specified replacement [7][9].

Omega-3 EPA/DHA trials illustrate dose- and formulation-dependence just as starkly. REDUCE-IT used 4 g/day purified EPA (icosapent ethyl) in patients with elevated triglycerides on statins and found a 25% relative risk reduction in MACE, with circulating EPA level inversely correlated with MACE risk [24]. VITAL (1 g/day mixed EPA+DHA, primary prevention) found no significant reduction in the composite primary endpoint, though MI itself was significantly reduced [26]. ASCEND (diabetes, no prior CVD) likewise found no significant reduction in overall major vascular events with moderate-dose omega-3 [25]. STRENGTH and OMEMI (combined EPA+DHA) found no benefit in high-risk populations, contrasting with REDUCE-IT's high-dose EPA-only design [24][25]. A pooled meta-analysis of 25 RCTs found moderate combined EPA+DHA doses (predominantly <1.8 g/day) do not significantly reduce MACE — plausibly because background statin/antiplatelet therapy attenuates incremental benefit — while high-dose purified EPA shows more robust effects in hypertriglyceridemic patients [24]. Whether REDUCE-IT reflects a true EPA-specific benefit or partly a comparator artifact (the mineral-oil placebo modestly raised control-arm LDL-C) remains actively debated [24][27].

3.4 EPA versus DHA, fish versus supplements, dose-response, and the atrial fibrillation signal

EPA and DHA are not interchangeable. Cardiac-tissue data suggest EPA predominates in left-atrial inflammatory/oxidative signaling, while DHA is a major structural component of left-ventricular membranes whose peroxidation products may trigger cardiomyocyte apoptosis at high concentrations, and DPA is specific for left-ventricular dysfunction signaling [30]. EPA monotherapy shows more consistent MACE reduction than combined EPA+DHA in several analyses [24][29].

Fish versus supplements: populations with high oily-fish intake show markedly lower fatal-MI incidence, specific to fatty fish, baked or broiled — frying negates the benefit via trans-fat formation and endothelial impairment [27][33]. Whole fish delivers a nutrient matrix (protein, selenium, vitamin D, meat-displacement) that isolated capsules cannot replicate, plausibly explaining why cohort fish data are more consistently protective than supplement RCT data [27].

Dose-response for triglyceride lowering is roughly monotonic: therapeutic reduction requires 2–4 g/day, moderate doses (<1.8 g/day) give inconsistent benefit, and low doses (650–750 mg/day) are neutral but insufficient for hypertriglyceridemia, via increased LPL activity and PPAR-mediated β-oxidation [24][25]. This gradient tracks a dose-dependent rise in atrial fibrillation risk (pooled OR ≈1.48 for >1.5 g/day) — cardioprotection and arrhythmia risk rise together, a genuine trade-off [24][30][31].

3.5 De novo lipogenesis and fatty-acid oxidation

De novo lipogenesis (DNL) is hepatic (and, to a lesser extent, adipose) synthesis of fatty acids from acetyl-CoA, transcriptionally driven by SREBP1c (insulin-responsive) and ChREBP (glucose-responsive); chronic DNL upregulation — classically provoked by high refined-carbohydrate, high-fructose intake — is mechanistically linked to hypertriglyceridemia, NAFLD, and cardiovascular risk [39], and is the biochemical basis for why substituting saturated fat with refined carbohydrate fails to improve, and can worsen, the atherogenic lipid profile (§3.3) [7][39].

Mitochondrial β-oxidation is the primary catabolic fate of fatty acids, yielding substantially more ATP per mole than glucose oxidation. Long-chain fatty acids require the carnitine shuttle to cross the impermeable inner mitochondrial membrane: CPT1 (outer membrane, rate-limiting) converts fatty-acyl-CoA to acylcarnitine; CACT exchanges it across the inner membrane; CPT2 regenerates acyl-CoA in the matrix [40]. Medium-chain fatty acids (C6–C12) bypass CPT1 entirely, entering mitochondria independent of carnitine — the basis for their more rapid, less regulated oxidation and ketogenic potential [41]. Once inside, four repeating enzymatic steps (chain-length-specific acyl-CoA dehydrogenases VLCAD/MCAD/SCAD → enoyl-CoA hydratase → 3-hydroxyacyl-CoA dehydrogenase → 3-ketothiolase) shorten the chain by two carbons per cycle, releasing acetyl-CoA, NADH, and FADH₂ for the TCA cycle and electron transport chain [40]. PPARα/PGC-1α are the master transcriptional regulators; saturated long-chain fatty acids (C16:0, C18:0) can suppress PPARα activity, while unsaturated fatty acids act as PPARα ligands promoting their own oxidation — a plausible contributor to differential fat-source effects on hepatic fat accumulation [40][42].

4. Clinical Relevance

Nearly every adult patient will ask, directly or indirectly, "is butter bad for me," "should I take fish oil," or "are eggs okay." This framework lets a clinician answer with the actual evidence rather than the loudest headline: saturated fat's risk is comparator-dependent, largest when replaced by refined carbohydrate rather than unsaturated fat or whole grains [7][9]; trans fat has essentially no defensible dietary role [7][13]; omega-3 supplementation is a legitimate but narrow-indication therapy (hypertriglyceridemia, HFrEF, high-risk secondary prevention at pharmacologic doses) rather than a universal supplement, and carries a real, dose-linked arrhythmia risk [24][30]; and egg/cholesterol counseling should center on overall dietary pattern rather than egg count alone [34][36]. As apoB and Lp(a) become routine clinical labs, understanding what they add over standard panels equips clinicians to use and explain modern risk stratification [4].

5. Evidence Review

Established (high confidence):

• ApoB is a superior, particle-based marker of atherogenic risk and Lp(a) is an independent, largely genetically-determined, causal contributor to atherosclerotic and valvular disease. evidence_strength: moderate, consensus_level: mixed [2][4].
• Industrial trans fat adversely affects the full lipid/inflammatory profile and its removal from food supplies has measurably reduced CVD mortality. evidence_strength: moderate, consensus_level: moderate [7][13][51].
• Moderate egg intake (~1/day) is not a major independent CVD driver for most healthy adults; saturated fat is a stronger LDL-C driver than dietary cholesterol per se. evidence_strength: strong, consensus_level: moderate [34][36].

Probable:

• Replacing SFA with PUFA or whole-grain carbohydrate reduces non-fatal MI risk, concentrated in higher-baseline-risk individuals; replacing SFA with refined carbohydrate does not. evidence_strength: moderate, consensus_level: moderate [7][9].
• Fermented-dairy SFA behaves more neutrally/protectively than SFA from red or processed meat — the food matrix modifies the SFA-CVD relationship. evidence_strength: strong, consensus_level: moderate [46][47][48].
• MUFA (olive oil) modestly improves LDL-C, apoA-I, blood pressure, and endothelial function when substituted for SFA. evidence_strength: strong, consensus_level: moderate [16][17][18].
• High-dose purified EPA reduces MACE in high-risk, high-triglyceride statin patients (REDUCE-IT); this does not generalize to moderate-dose EPA+DHA in lower-risk primary prevention (VITAL, ASCEND, STRENGTH, OMEMI). evidence_strength: strong, consensus_level: moderate [24][25][26].
• Omega-3 supplementation ≥1.5–4 g/day dose-dependently increases atrial fibrillation risk. evidence_strength: strong, consensus_level: moderate [24][30].

Emerging:

• EPA and DHA may have chamber-specific cardiac effects (EPA/left atrium vs. DHA-DPA/left ventricle) — plausible but with limited direct outcome-trial testing [30].
• Whether whole-fish consumption confers benefit beyond isolated EPA/DHA via its broader nutrient matrix is biologically plausible but not resolved by head-to-head trials [27][33].

Controversial:

• Omega-6 linoleic acid: net anti-inflammatory/cardioprotective (dominant guideline position, RCTs show reduced CRP/stroke risk) versus meaningfully displacing omega-3 status and shifting eicosanoid balance pro-inflammatory (controlled-feeding RCT evidence). evidence_strength: strong, consensus_level: moderate — strong evidence on both sides of a genuinely unresolved question [12][21][22][23].
• Whether REDUCE-IT's MACE benefit is a true EPA-specific effect or partly a mineral-oil comparator artifact remains actively debated [24][27].

Unsupported / overstated:

• Treating "saturated fat" as monolithic and uniformly harmful irrespective of chain length, food matrix, or comparator [7][10][46][48].
• Treating fish-oil supplementation as universally beneficial and risk-free, given neutral primary-prevention results and the dose-linked atrial fibrillation signal [25][26][30].

6. Practical Clinical Applications

When to counsel saturated fat reduction: Most beneficial as a substitution — unsaturated plant oils, nuts, fatty fish, or fermented dairy in place of refined starch/sugar — and most impactful in patients with elevated baseline ASCVD risk (high LDL-C/apoB, existing atherosclerotic disease, diabetes) [7][9].

When to check apoB/Lp(a): Order apoB when LDL-C and triglycerides are discordant (e.g., high triglycerides with "normal" LDL-C, common in insulin resistance), and Lp(a) once in adulthood, especially with premature ASCVD or family history. Lp(a) is not meaningfully diet-modifiable — communicate this clearly to avoid patient frustration with lifestyle measures [4].

Omega-3 supplementation — targets and indications: Purified EPA (icosapent ethyl, 4 g/day) is indicated for established ASCVD or diabetes-plus-risk-factors with triglycerides ≥150 mg/dL despite statins [24][28]. Lower doses (~1 g/day) have an indication in HFrEF for reducing mortality/hospitalization [25]. Routine high-dose supplementation for primary prevention in low-risk adults is not supported by VITAL/ASCEND-level evidence [25][26].

Drug interactions and cautions: Pharmacologic-dose omega-3s have mild antiplatelet activity and may add to bleeding risk with anticoagulants/antiplatelets — monitor accordingly [24]. High-dose omega-3 (≥1.5–4 g/day) requires disclosing atrial fibrillation risk, especially with existing AF risk factors [24][30]. Statin co-therapy is standard background treatment in the major trials; omega-3s are adjunctive, not a statin substitute [24][25].

Eggs/dietary cholesterol: For most healthy adults, up to ~1 egg/day fits cardioprotective dietary patterns; counsel around overall diet (what eggs replace) rather than egg count alone, noting a modestly elevated risk signal in some postmenopausal-women and diabetes data that warrants individualized discussion [34][35][36].

7. Clinical Pearls

• "Saturated fat is bad" is an incomplete sentence — always ask "replaced with what?" The same gram of saturated fat removed can be cardioprotective (if replaced by PUFA/MUFA/whole grain) or neutral-to-harmful (if replaced by refined carbohydrate) [7][9].
• Cheese and yogurt are not butter: the food matrix around dairy saturated fat measurably changes its cardiovascular association [46][48].
• REDUCE-IT ≠ VITAL ≠ ASCEND: dose, formulation (EPA-only vs. EPA+DHA), and baseline risk explain why "omega-3 trials are conflicting" is a comparator problem, not a coin flip [24][25][26].
• Higher-dose omega-3 buys MACE reduction and atrial fibrillation risk simultaneously — this is a real trade-off to disclose, not a technicality [24][30].
• ApoB resolves LDL-C/triglyceride discordance; Lp(a) should be checked once and is not a lifestyle target [4].

8. Common Misconceptions

• "All saturated fat is equally harmful." Chain length and food source (meat vs. fermented dairy) meaningfully modify risk [10][46][48].
• "Seed oils are inflammatory and dangerous because of omega-6." The dominant RCT evidence shows LA-rich oil substitution for saturated fat lowers CRP and stroke risk; the competing omega-3-displacement hypothesis is real but not synonymous with net harm [12][21][22].
• "Fish oil supplements are essentially risk-free and good for everyone's heart." Primary-prevention trials (VITAL, ASCEND) were neutral for the primary composite endpoint, and high-dose regimens carry a genuine atrial fibrillation signal [25][26][30].
• "Eggs are as dangerous as smoking for your heart." Moderate egg intake is not associated with meaningfully increased CVD risk in most populations; saturated fat, not dietary cholesterol, is the stronger LDL-C driver [34][36].
• "HDL cholesterol level alone tells you cardiovascular risk." HDL particle function (e.g., CETP activity) can diverge from HDL-C concentration [5].

9. Summary

Lipoprotein metabolism is a transport system — chylomicrons and VLDL deliver triglyceride, LDL delivers cholesterol, HDL returns it — and cardiovascular risk tracks apoB particle number more precisely than any single cholesterol concentration, with Lp(a) as a separate, largely genetic, causal contributor [2][4]. Dietary fatty acid classes are not interchangeable: trans fat is essentially unambiguously harmful, saturated fat's effect depends entirely on its comparator and food matrix, MUFA and PUFA are generally protective when they displace saturated fat, and the omega-3/omega-6 relationship remains genuinely contested [7][12][13][46]. The omega-3 EPA/DHA trial literature — REDUCE-IT, VITAL, ASCEND, STRENGTH, OMEMI — is not simply "conflicting" but explicable by systematic differences in dose, formulation, and baseline risk, with a real dose-linked trade-off between MACE reduction and atrial fibrillation [24][25][26][30]. At the biochemical core, de novo lipogenesis and mitochondrial β-oxidation are the opposing pathways determining whether excess dietary energy — particularly refined carbohydrate — is stored as triglyceride or oxidized for fuel, explaining why substitution for saturated fat matters as much as its removal [7][39][40]. Clinicians who master this framework can move patients past "fat is good/fat is bad" toward a precise, individualized conversation about lipid risk.

10. References

Ordered by evidence strength / relevance. Evidence level and AllNutrition trust score (0–1) as returned by the tool.

1. Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis. Circulation Research (2026). Review — trust 0.925.
2. Emerging biomedical and pharmaceutical strategies for the treatment of atherosclerosis: from conventional lipid-lowering therapy to nanomedicine. Journal of Applied Biomedicine (2026). Review — trust 0.833.
3. The lysophosphatidylcholine-HIF-1α axis enhances apolipoprotein E sialylation and promotes electronegative LDL accumulation. iScience (2026). Observational — trust 0.887.
4. Re-evaluating Cardiovascular Risk: A Narrative Review Challenging the Cholesterol Hypothesis and Identifying Modern Dietary Drivers. Cureus (2026). Review — trust 0.633.
5. Dissociation Between Cholesteryl Ester Transfer Protein Mass and Activity in Coronary Artery Disease Patients with Elevated High-Density Lipoprotein Cholesterol. The Anatolian Journal of Cardiology (2026). Observational — trust 0.67.
6. A Case of Familial Chylomicronemia Syndrome Caused by a Novel Homozygous GPIHBP1 Mutation Successfully Treated with the Selective PPARα Modulator Pemafibrate. Journal of Atherosclerosis and Thrombosis (2026). Observational — trust 0.708.
7. Concerns about the health effects of industrially produced seed oils are without scientific foundation: a scoping narrative review of the clinical and observational evidence. Critical Reviews in Food Science and Nutrition (2026). Review — trust 0.637.
8. Dietary fatty acids in the secondary prevention of coronary heart disease: a systematic review, meta-analysis and meta-regression. BMJ Open (2014). Systematic review — trust 0.595.
9. Diet, the protective bridge connecting nutrition and cardiovascular health: A review. Food Chemistry: X (2026). Review — trust 0.73.
10. Fatty Acids and Their Roles in Cardiac Physiology and Pathology: Mechanistic and Interventional Studies. Nutrients (2026). Review — trust 0.715.
11. A Critical Narrative Review Appraisal of the 2025–2030 Dietary Guidelines. Nutrients (2026). Review — trust 0.705.
12. A Clinician's Guide for Trending Cardiovascular Nutritional Controversies in 2026. JACC: Advances (2026). Review — trust 0.765.
13. Impact of diets high in trans-fatty acids on cardiovascular diseases in adults aged 55 and older: insights from the Global Burden of Disease 2021 data. Frontiers in Nutrition (2026). Observational — trust 0.767.
14. The impact of dietary fat and fatty acid consumption on human health: A comprehensive review of meta-analyses and the Global Burden of Disease study 2021. Trends in Food Science & Technology (2025). Review — trust 0.717.
15. Effects of high-oleic dietary interventions on cardiometabolic outcomes in adults: a GRADE-based systematic review and meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome (2026). Systematic review — trust 0.807.
16. The effect of oleic acid enriched diets on glucose and lipid metabolism: a systematic review and meta-analysis. Nutrition & Metabolism (2026). Systematic review — trust 0.857.
17. Exploring the Benefits of Extra Virgin Olive Oil on Cardiovascular Health Enhancement and Disease Prevention: A Systematic Review. Nutrients (2025). Systematic review — trust 0.782.
18. Olive oil compounds: biological and chemical actions for health — an updated review. Food Chemistry Advances (2026). Review — trust 0.695.
19. Mediterranean diet versus low-fat diet on cardiovascular disease (CVD) risk factors and outcomes: A systematic review of RCTs. Medicine (2026). Systematic review — trust 0.875.
20. Associations between n-3 and n-6 polyunsaturated fatty acids and stroke risk, mediated by the dietary inflammatory index: Evidence from NHANES 2007-2018. Journal of Stroke and Cerebrovascular Diseases (2026). Observational — trust 0.752.
21. Effect of Dietary Linoleic Acid Intake on Eicosapentaenoic Acid Status and Lipoxygenase-Mediated Oxylipin Biosynthesis in Healthy Adults: A Randomized Controlled Trial. Nutrients (2026). RCT — trust 0.875.
22. Adipose tissue content of ω-6 polyunsaturated fatty acids and all-cause mortality: A Danish prospective cohort study. The American Journal of Clinical Nutrition (2025). Observational — trust 0.762.
23. Meta Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk. Pharmacology Research & Perspectives (2026). Systematic review — trust 0.827.
24. The Role of Omega-3 and Omega-6 Polyunsaturated Fatty Acid Supplementation in Human Health. Foods (2025). Review — trust 0.695.
25. Global burden of ischemic heart disease due to omega-3 deficiency: 204-country analysis, 1990–2021. Frontiers in Nutrition (2025). Observational — trust 0.767.
26. Mediterranean diet: The role of long-chain v-3 fatty acids in fish; polyphenols in fruits, vegetables, cereals, coffee, tea, cacao and wine; probiotics and vitamins in prevention of stroke, age-related cognitive decline, and Alzheimer disease. Revue Neurologique (2019). Review — trust 0.603.
27. European Medicines Agency versus Italian Medicines Agency indications for icosapent ethyl: a long and winding road. Nutrition, Metabolism and Cardiovascular Diseases (2026). Observational — trust 0.65.
28. Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits. Current Nutrition Reports (2026). Review — trust 0.833.
29. Association between circulating ω-3 polyunsaturated fatty acid levels and left cardiac myocardial strain in hypertension: a CMR-FT study. Frontiers in Nutrition (2026). Observational — trust 0.625.
30. Association Between Plasma Omega-3 and Omega-6 Fatty Acid Levels and Atrial Fibrillation: A Large-Scale, Real-World Retrospective Study in Japan. Journal of Atherosclerosis and Thrombosis (2026). Observational — trust 0.77.
31. Association of fish intake with systemic immune-inflammation index: Potential mediating role of n-3 polyunsaturated fatty acids. Prostaglandins & Leukotrienes and Essential Fatty Acids (2026). Observational — trust 0.613.
32. Eggs as a Nutrient-Rich Food with Potential Relevance to Sleep, Metabolic Health, and Well-Being During the Menopausal Transition: A Narrative Review. Nutrients (2025). Review — trust 0.685.
33. El huevo en la mesa familiar y su impacto en la salud infantil y adolescente. Nutrición Hospitalaria (2026). Review — trust 0.637.
34. Reducing dietary fat and cholesterol is clinically important to maintain or lower serum LDL cholesterol concentrations to optimal levels (and accompanying Reply to Letter to the Editor). The American Journal of Clinical Nutrition (2025). Observational/Review — trust 0.732 / 0.765.
35. H2S-mediated protein S-sulfhydration: a novel regulatory module in lipid metabolism. Frontiers in Cell and Developmental Biology (2026). Review — trust 0.65.
36. Mitochondrial fatty acid oxidation: a new perspective on metabolic regulation in respiratory diseases. International Immunopharmacology (2026). Review — trust 0.637.
37. Advancing lipid nutrition for type 2 diabetes: the critical role of medium- and long-chain triglycerides in modulating lipid metabolism, insulin resistance, and ketogenesis. Food Bioscience (2026). Review — trust 0.695.
38. Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging. Molecular and Cellular Endocrinology (2016). Review — trust 0.65.
39. Nutritional advice for patients with obesity and prediabetes. Best Practice & Research Clinical Endocrinology & Metabolism (2026). Review — trust 0.662.
40. Quantitative comparison of food-based dietary guidelines: alignment with the Slovenian nutrition guidelines 2025 and Slovenian intake. European Journal of Nutrition (2026). Review — trust 0.76.
41. What Europe should (not) learn from the new Dietary Guidelines for Americans. Acta Clinica Belgica (2026). Review — trust 0.9.
42. Dairy consumption and cardiovascular disease risk: a multi-level analysis with inflammatory biomarker mediation. Nutrition & Metabolism (2025). Observational — trust 0.745.
43. Associations of the consumption of unprocessed red meat and processed meat with the incidence of cardiovascular disease and mortality, and the dose-response relationship: A systematic review and meta-analysis of cohort studies. Critical Reviews in Food Science and Nutrition (2023). Systematic review — trust 0.843.
44. Dietary Patterns Influence Chronic Disease Risk and Health Outcomes in Older Adults: A Narrative Review. Nutrients (2025). Review — trust 0.695.
45. Evaluating Trans-Fatty Acids Labelling in Packaged Foods Sold in Brazil Before and After National Policy Changes. Journal of Human Nutrition and Dietetics (2026). Observational — trust 0.887.

Supporting sources also surfaced: Associations of Serum Fatty Acids and the EPA/AA Ratio with Hypertriglyceridemia in a Japanese Population (J Atheroscler Thromb 2026, observational, trust 0.637); Lipid-lowering and anti-inflammatory effects of omega-3 ethyl esters and krill oil (Arch Med Sci 2016, RCT, trust 0.712); Omega-3 fatty acids improve lipid metabolism by regulating miR-34a (Sci Rep 2026, observational, trust 0.77); Inverse Association between the Omega-3 Index and Neutrophil–Lymphocyte Ratio (J Nutr 2026, RCT, trust 0.7); Omega-3 Index: an emerging biomarker in cardiovascular prevention (Nutr Hosp 2023, review, trust 0.637); Regulatory heterogeneity, trade mediation and nutrient intake: The case of Trans fat (Food Policy 2026, observational, trust 0.767); Methodological challenges in translating nutrition evidence into the Australian Dietary Guidelines (Br J Nutr 2026, review, trust 0.7).

---

Note on tool reliability during research: two ask_nutrition calls timed out and were re-queried successfully; a small number of parallel calls returned mismatched/crossed answers (unrelated topics), which were discarded and re-run individually before being used in this module. Only correctly-matched, verified tool outputs were cited above.